Iovance Biotherapeutics Inc (LTS:0JDK)
$ 11.29 0.295 (2.68%) Market Cap: 3.48 Bil Enterprise Value: 3.15 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 30/100

Iovance Biotherapeutics Inc at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit (Virtual) Transcript

Apr 26, 2022 / 05:30PM GMT
Release Date Price: $16.55 (+3.76%)
Yevgeniya Livshits
Chardan Capital Markets, LLC, Research Division - Senior Research Analyst

Good afternoon. It's now my pleasure to introduce our next fireside chat guest, Dr. Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics. The format for this session is roughly 25-minute fireside chat, but we'll begin with some high-level overview slides of Iovance and its manufacturing capabilities before jumping into the discussion. (Operator Instructions) Igor, welcome. Please go ahead.

Igor P. Bilinsky
Iovance Biotherapeutics, Inc. - COO

Thank you, Geulah. Great to be here, and good afternoon, everyone. So I'll start with a brief intro of Iovance and our manufacturing capabilities. We are a publicly listed company, and I'll be making forward-looking statements as part of this presentation and for a full disclosure of risks and uncertainties associated with investing in Iovance, please refer to our SEC filings.

So Iovance, we're a global leader in innovating, developing and delivering TIL, or tumor-infiltrating lymphocyte therapies for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot